| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:LLY) revealed 23 unusual trades.
Delving into the details, we found 47% of traders were bullish, while 39% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $254,892, and 19 were calls, valued at $1,227,011.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $610.0 to $900.0 for Eli Lilly over the last 3 months.
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $610.0 to $900.0 in the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | SWEEP | BULLISH | 10/31/25 | $19.3 | $17.05 | $19.3 | $817.50 | $264.4K | 76 | 138 |
| LLY | PUT | SWEEP | BEARISH | 01/16/26 | $36.15 | $34.9 | $36.15 | $800.00 | $214.9K | 2.7K | 72 |
| LLY | CALL | TRADE | BULLISH | 01/16/26 | $218.9 | $218.9 | $218.9 | $610.00 | $131.3K | 97 | 6 |
| LLY | CALL | TRADE | BEARISH | 11/07/25 | $11.4 | $10.0 | $10.5 | $850.00 | $105.0K | 383 | 239 |
| LLY | CALL | TRADE | BEARISH | 11/07/25 | $21.85 | $20.15 | $20.6 | $820.00 | $103.0K | 143 | 33 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
After a thorough review of the options trading surrounding Eli Lilly, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $973.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Eli Lilly with a target price of $948. * An analyst from Morgan Stanley persists with their Overweight rating on Eli Lilly, maintaining a target price of $1023. * Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $948.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with Benzinga Pro for real-time alerts.
Posted In: LLY
